Brain metastases recruit suppressive immune cells via novel pathway to facilitate their growth
MD Anderson researchers have discovered that metastatic cancer cells in the brain upregulate expression of the EZH2 gene to activate a previously unknown pathway and recruit immune-suppressive neutrophils to the brain, allowing metastatic cells to thrive. The study, published in Science Translational Medicine, suggests that targeting this neutrophil recruitment may be a useful strategy for treating brain metastases.
“To gain...
ASCO: Palliative and supportive care interventions increase comfort in advanced cancer patients
Two studies presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted MD Anderson’s commitment to holistic...
ASCO: Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers
Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate...
ASCO: Developing effective combination therapies for leukemia
Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...
ASCO: Studies pave the way on immunotherapy clinical trials for rare, aggressive cancers
Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide...
ASCO: Emerging targeted therapies show signs of clinical activity across multiple cancer types
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
ASCO: Studies show advances in treatment and understanding of BRCA-associated and triple-negative breast cancer
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival...
Phase I clinical trial shows WNT974 in combination with spartalizumab well tolerated for advanced solid tumor patients
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
Study shows naproxen promotes immune activation in Lynch syndrome patients
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...